# Chemclin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chemclin

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.chemclin.com
- Total disclosed funding: $22M
- Latest round: Series B (Oct 20, 2008)
- Investors on record: 4

## About

Chemclin, based in China, develops and manufactures advanced chemical solutions for various industrial applications, focusing on specialty chemicals that improve efficiency and meet regulatory standards.Founded in 2007 and headquartered in Beijing, China, Chemclin specializes in advanced chemical solutions. The company has undergone a restructuring process recently and has successfully raised CNY 2,000.00 mn in its latest funding round led by Huaxing Growth Capital and Legend Capital. It has executed a total of 5 investment deals to date. Lin Li serves as the CEO.Chemclin offers a wide range of advanced chemical solutions tailored for industrial applications. Its core offerings include specialty chemicals and formulations utilized in the pharmaceuticals, agriculture, and manufacturing sectors, aiming to overcome specific challenges such as enhancing product stability and increasing agricultural yields. The company serves markets across North America, Europe, and parts of Asia, ensuring compliance with stringent regulatory requirements.Chemclin generates revenue through a B2B model, supplying products directly to manufacturers and distributors. This includes long-term contracts, bulk purchasing agreements, and subscription-based engagements for ongoing supply needs. Tailored pricing plans support larger clients requiring customized formulations, with the flagship product line significantly contributing to overall revenue.Chemclin is focused on expanding its product offerings, with new specialty chemicals slated for launch in the coming year. The company is also targeting expansion into emerging markets in Southeast Asia by the end of 2024. The recent CNY 2,000.00 mn raised from the restructuring will be allocated towards these initiatives, enhancing production capabilities and market reach.

## Funding rounds

- Series B, Oct 20, 2008, $17M — N47, SB China Venture Capital, WI Harper Group, ECON Healthcare Group
- Series A, Jun 4, 2007, $5M — N47, SB China Venture Capital, WI Harper Group

## Investors

- N47 (https://capitalatlas.ai/funds/n47) — Series A, Series B
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series A, Series B
- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series A, Series B
- ECON Healthcare Group — Series B